239 related articles for article (PubMed ID: 35188645)
21. Adverse outcome pathways (AOPs) for radiation-induced reproductive effects in environmental species: state of science and identification of a consensus AOP network.
Tollefsen KE; Alonzo F; Beresford NA; Brede DA; Dufourcq-Sekatcheff E; Gilbin R; Horemans N; Hurem S; Laloi P; Maremonti E; Oughton D; Simon O; Song Y; Wood MD; Xie L; Frelon S
Int J Radiat Biol; 2022; 98(12):1816-1831. PubMed ID: 35976054
[TBL] [Abstract][Full Text] [Related]
22. Adverse outcome pathways: From research to regulation scientific workshop report.
Kleinstreuer NC; Sullivan K; Allen D; Edwards S; Mendrick DL; Embry M; Matheson J; Rowlands JC; Munn S; Maull E; Casey W
Regul Toxicol Pharmacol; 2016 Apr; 76():39-50. PubMed ID: 26774756
[TBL] [Abstract][Full Text] [Related]
23. Adverse outcome pathways: opportunities, limitations and open questions.
Leist M; Ghallab A; Graepel R; Marchan R; Hassan R; Bennekou SH; Limonciel A; Vinken M; Schildknecht S; Waldmann T; Danen E; van Ravenzwaay B; Kamp H; Gardner I; Godoy P; Bois FY; Braeuning A; Reif R; Oesch F; Drasdo D; Höhme S; Schwarz M; Hartung T; Braunbeck T; Beltman J; Vrieling H; Sanz F; Forsby A; Gadaleta D; Fisher C; Kelm J; Fluri D; Ecker G; Zdrazil B; Terron A; Jennings P; van der Burg B; Dooley S; Meijer AH; Willighagen E; Martens M; Evelo C; Mombelli E; Taboureau O; Mantovani A; Hardy B; Koch B; Escher S; van Thriel C; Cadenas C; Kroese D; van de Water B; Hengstler JG
Arch Toxicol; 2017 Nov; 91(11):3477-3505. PubMed ID: 29051992
[TBL] [Abstract][Full Text] [Related]
24. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
Sachana M; Willett C; Pistollato F; Bal-Price A
Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
[TBL] [Abstract][Full Text] [Related]
25. A high-level overview of the OECD AOP Development Programme.
Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
[TBL] [Abstract][Full Text] [Related]
26. Derivation, characterisation and analysis of an adverse outcome pathway network for human hepatotoxicity.
Arnesdotter E; Spinu N; Firman J; Ebbrell D; Cronin MTD; Vanhaecke T; Vinken M
Toxicology; 2021 Jul; 459():152856. PubMed ID: 34252478
[TBL] [Abstract][Full Text] [Related]
27. Putative adverse outcome pathways of the male reproductive toxicity derived from toxicological studies of perfluoroalkyl acids.
Lu T; Mortimer M; Li F; Li Z; Chen L; Li M; Guo LH
Sci Total Environ; 2023 May; 873():162439. PubMed ID: 36848992
[TBL] [Abstract][Full Text] [Related]
28. Overview of Adverse Outcome Pathways and Current Applications on Nanomaterials.
Rolo D; Tavares A; Vital N; Silva MJ; Louro H
Adv Exp Med Biol; 2022; 1357():415-439. PubMed ID: 35583654
[TBL] [Abstract][Full Text] [Related]
29. Adverse outcome pathways: a concise introduction for toxicologists.
Vinken M; Knapen D; Vergauwen L; Hengstler JG; Angrish M; Whelan M
Arch Toxicol; 2017 Nov; 91(11):3697-3707. PubMed ID: 28660287
[TBL] [Abstract][Full Text] [Related]
30. An integrative data-centric approach to derivation and characterization of an adverse outcome pathway network for cadmium-induced toxicity.
Sahoo AK; Chivukula N; Ramesh K; Singha J; Marigoudar SR; Sharma KV; Samal A
Sci Total Environ; 2024 Apr; 920():170968. PubMed ID: 38367714
[TBL] [Abstract][Full Text] [Related]
31. Investigation of a derived adverse outcome pathway (AOP) network for endocrine-mediated perturbations.
Ravichandran J; Karthikeyan BS; Samal A
Sci Total Environ; 2022 Jun; 826():154112. PubMed ID: 35219661
[TBL] [Abstract][Full Text] [Related]
32. The First Steps on AOPs' Concepts, Development, and Applications in Teratology.
Vieira L; Souza T; Farias D
Methods Mol Biol; 2024; 2753():151-157. PubMed ID: 38285337
[TBL] [Abstract][Full Text] [Related]
33. A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis.
Verhoeven A; van Ertvelde J; Boeckmans J; Gatzios A; Jover R; Lindeman B; Lopez-Soop G; Rodrigues RM; Rapisarda A; Sanz-Serrano J; Stinckens M; Sepehri S; Teunis M; Vinken M; Jiang J; Vanhaecke T
Toxicology; 2024 Jun; 505():153814. PubMed ID: 38677583
[TBL] [Abstract][Full Text] [Related]
34. Linking Mitochondrial Dysfunction to Organismal and Population Health in the Context of Environmental Pollutants: Progress and Considerations for Mitochondrial Adverse Outcome Pathways.
Dreier DA; Mello DF; Meyer JN; Martyniuk CJ
Environ Toxicol Chem; 2019 Aug; 38(8):1625-1634. PubMed ID: 31034624
[TBL] [Abstract][Full Text] [Related]
35. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?
Marty S; Beekhuijzen M; Charlton A; Hallmark N; Hannas BR; Jacobi S; Melching-Kollmuss S; Sauer UG; Sheets LP; Strauss V; Urbisch D; Botham PA; van Ravenzwaay B
Crit Rev Toxicol; 2021 Apr; 51(4):328-358. PubMed ID: 34074207
[TBL] [Abstract][Full Text] [Related]
36. Investigating fatty liver disease-associated adverse outcome pathways of perfluorooctane sulfonate using a systems toxicology approach.
Kim M; Kim SH; Choi JY; Park YJ
Food Chem Toxicol; 2023 Jun; 176():113781. PubMed ID: 37059384
[TBL] [Abstract][Full Text] [Related]
37. Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity.
Bal-Price A; Meek MEB
Pharmacol Ther; 2017 Nov; 179():84-95. PubMed ID: 28529068
[TBL] [Abstract][Full Text] [Related]
38. Differentiating Pathway-Specific From Nonspecific Effects in High-Throughput Toxicity Data: A Foundation for Prioritizing Adverse Outcome Pathway Development.
Fay KA; Villeneuve DL; Swintek J; Edwards SW; Nelms MD; Blackwell BR; Ankley GT
Toxicol Sci; 2018 Jun; 163(2):500-515. PubMed ID: 29529260
[TBL] [Abstract][Full Text] [Related]
39. Adverse outcome pathway from activation of the AhR to breast cancer-related death.
Benoit L; Jornod F; Zgheib E; Tomkiewicz C; Koual M; Coustillet T; Barouki R; Audouze K; Vinken M; Coumoul X
Environ Int; 2022 Jul; 165():107323. PubMed ID: 35660951
[TBL] [Abstract][Full Text] [Related]
40. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
Becker RA; Ankley GT; Edwards SW; Kennedy SW; Linkov I; Meek B; Sachana M; Segner H; Van Der Burg B; Villeneuve DL; Watanabe H; Barton-Maclaren TS
Regul Toxicol Pharmacol; 2015 Aug; 72(3):514-37. PubMed ID: 25863193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
